XERS — Xeris Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1867096 ·
Last close
$16.80
Market Cap
$3.07B
52W High
$16.98
52W Low
$5.25
ADV30
3,065,584
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 92,100,000 | 79,588,000 | 5,173,000 | -31,101,000 | 411,905,000 | 121,747,000 | 421,639,000 |
| Mar 2026 | 83,127,000 | 72,553,000 | 7,916,000 | 2,234,000 | 392,013,000 | 111,750,000 | 379,002,000 |
| Dec 2025 | 85,807,000 | 74,860,000 | 16,773,000 | 11,081,000 | 383,527,000 | 111,042,000 | 369,838,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$56,608,000
Investing CF
$-938,000
Financing CF
$6,690,000
CapEx
$-938,000
Dividends Paid
—
Buybacks
$-19,226,000
EPS Diluted TTM
$-0.05
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-700,174,000
Inventory
$80,930,000
Receivables
$58,105,000
ST Investments
—
EBIT TTM
$11,087,000
Pretax Income TTM
$-17,165,000
Interest Exp TTM
$28,252,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$368,259,008
EBITDA
$58,929,000
Free Cash Flow
$52,450,124
Enterprise Value
$2,872,024,576
Total Cash
$131,082,000
Total Debt
$226,066,000
Shares Out
182,700,038
Trailing EPS
$-0.03
Book Value
$0.27
ROE
-27.1%
ROA
7.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 291,845,000 | 24,896,000 | 554,000 | 383,527,000 | 369,838,000 | 13,689,000 | 28,626,000 |
| Dec 2024 | 203,070,000 | -33,646,000 | -54,836,000 | 323,060,000 | 352,675,000 | -29,615,000 | -36,981,000 |
| Dec 2023 | 163,914,000 | -44,010,000 | -62,255,000 | 322,602,000 | 329,384,000 | -6,782,000 | -47,023,000 |
| Dec 2022 | 110,248,000 | -81,940,000 | -94,660,000 | 344,522,000 | 299,335,000 | 45,187,000 | -102,891,000 |
TTM Snapshot
Revenues TTM
$335,414,000
NetIncome TTM
$-17,165,000
OpCashFlow TTM
—
Assets (Latest)
$411,905,000
Forward EPS
$0.27
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $11.00 · spot: $16.99 · call volume: 4,244 · put volume: 11
Expected Move to 2027-01-15:
±$5.03
(29.61%) —
implied range
$11.96 –
$22.02
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BGM | BGM Group Ltd. | $3.09B | $8.13 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.01B | $8.85 | — |
| LEGN | Legend Biotech Corp | $3.13B | $16.11 | — |
| DYN | Dyne Therapeutics, Inc. | $3.00B | $16.02 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.17B | $18.32 | — |
News headlines (Yahoo Finance, 1h cache)
Xeris Biopharma Holdings (XERS) Stock May Be Worth More Following Raised Revenue Guidance
2026-11-18 02:18 · Yahoo
XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
2026-11-11 18:23 · Yahoo
Is Xeris Biopharma Holdings (XERS) Overpriced After Its Q3 Beat And 2026 Outlook Raise?
2026-11-07 18:13 · Yahoo
Xeris Biopharma (XERS) Adds Menassie M. Taddese To Its Board
2026-11-07 11:13 · Yahoo
Xeris Biopharma Q3 Earnings Call Highlights
2026-11-06 23:14 · Yahoo
Xeris Biopharma Holdings Inc (XERS) (Q3 2026) Earnings Call Highlights: Revenue Surges 44% as ...
2026-11-06 21:08 · Yahoo
Xeris Biopharma Holdings, Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:47 · Yahoo
Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript
2026-11-05 21:34 · Yahoo
Xeris CEO Sees Recorlev Nearing $1B In Annual Sales 3 To 4 Years Earlier Than Expected – XERS Stock On Track To Hit Over 7-Year Highs
2026-11-05 13:55 · Yahoo
Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-05 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.